Home » Topics » BioWorld Science

BioWorld Science
RSS

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

April 4, 2022

Novel TLR4 murine model to study dermal sensitization by nickel salts

April 4, 2022

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

April 1, 2022

Humanized mouse model to asses acute toxicity of immune drug treatments

April 1, 2022

New orthotopic xenograft breast cancer murine models developed

April 1, 2022

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

April 1, 2022

Telomere to telomere, the human genome is done

April 1, 2022

RemeGen discloses new anti-c-Met antibody-drug conjugates

April 1, 2022

CNRS and collaborators patent acetylcholinesterase reactivators

April 1, 2022

New NFE2-related factor 2 activators described by Sanofi

April 1, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...